GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (BSP:T1CH34) » Definitions » Cyclically Adjusted Revenue per Share

Bio-Techne (BSP:T1CH34) Cyclically Adjusted Revenue per Share : R$0.70 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Bio-Techne Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bio-Techne's adjusted revenue per share for the three months ended in Dec. 2023 was R$0.278. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$0.70 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Bio-Techne's average Cyclically Adjusted Revenue Growth Rate was 11.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bio-Techne was 15.80% per year. The lowest was 8.60% per year. And the median was 11.35% per year.

As of today (2024-04-27), Bio-Techne's current stock price is R$10.95. Bio-Techne's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was R$0.70. Bio-Techne's Cyclically Adjusted PS Ratio of today is 15.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 9.38. And the median was 13.33.


Bio-Techne Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted Revenue per Share Chart

Bio-Techne Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.66 0.84 0.79

Bio-Techne Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.90 0.91 0.79 0.92 0.70

Competitive Comparison of Bio-Techne's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted PS Ratio falls into.



Bio-Techne Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.278/129.4194*129.4194
=0.278

Current CPI (Dec. 2023) = 129.4194.

Bio-Techne Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.050 99.695 0.065
201406 0.047 100.560 0.060
201409 0.057 100.428 0.073
201412 0.066 99.070 0.086
201503 0.080 99.621 0.104
201506 0.082 100.684 0.105
201509 0.098 100.392 0.126
201512 0.105 99.792 0.136
201603 0.108 100.470 0.139
201606 0.103 101.688 0.131
201609 0.094 101.861 0.119
201612 0.098 101.863 0.125
201703 0.100 102.862 0.126
201706 0.115 103.349 0.144
201709 0.100 104.136 0.124
201712 0.112 104.011 0.139
201803 0.117 105.290 0.144
201806 0.147 106.317 0.179
201809 0.144 106.507 0.175
201812 0.146 105.998 0.178
201903 0.152 107.251 0.183
201906 0.157 108.070 0.188
201909 0.160 108.329 0.191
201912 0.160 108.420 0.191
202003 0.201 108.902 0.239
202006 0.192 108.767 0.228
202009 0.230 109.815 0.271
202012 0.239 109.897 0.281
202103 0.281 111.754 0.325
202106 0.265 114.631 0.299
202109 0.275 115.734 0.308
202112 0.308 117.630 0.339
202203 0.294 121.301 0.314
202206 0.296 125.017 0.306
202209 0.291 125.227 0.301
202212 0.294 125.222 0.304
202303 0.316 127.348 0.321
202306 0.301 128.729 0.303
202309 0.282 129.860 0.281
202312 0.278 129.419 0.278

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Bio-Techne  (BSP:T1CH34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.95/0.7
=15.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bio-Techne was 34.02. The lowest was 9.38. And the median was 13.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bio-Techne Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne (BSP:T1CH34) Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Bio-Techne (BSP:T1CH34) Headlines

No Headlines